News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 11, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Appoints Ronald C. Renaud, Jr. to Board of Directors

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Ronald C. Renaud, Jr. to the company's Board of Directors. Mr. Renaud...

Jun 10, 2014, 16:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 9, 2014 it approved non-statutory stock options to purchase an aggregate of...

May 23, 2014, 07:53 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Receives Positive Opinion from CHMP for Translarna™ (ataluren)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for...

May 23, 2014, 07:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Provides EMA Update

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will provide an update on the re-examination of its marketing...

May 21, 2014, 16:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Jefferies 2014 Global Healthcare...

May 16, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation...

May 06, 2014, 16:01 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the first quarter ended...

Apr 23, 2014, 16:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Present at Upcoming Investor Conferences

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at two upcoming investor conferences:...

Apr 22, 2014, 16:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2014 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2014...

Apr 21, 2014, 13:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2014 it granted non-statutory stock options to purchase an aggregate...

Mar 06, 2014, 16:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and...

Feb 28, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics To Present At The Cowen & Company 34th Annual Health Care Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care...

Feb 27, 2014, 21:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it granted a non-statutory stock option to purchase 150,000 shares of its common stock...

Feb 27, 2014, 17:45 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Host Fourth Quarter and Year End 2013 Financial Results Conference Call

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that will host a webcast conference call to discuss financial results for the fourth...

Feb 25, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Expands International Commercial Team

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs...

Feb 20, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Present at Upcoming Investor Conferences

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences: - Management will...

Feb 19, 2014, 13:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Closing of Registered Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

 PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced registered public offering of 5,163,265 shares...

Feb 12, 2014, 20:33 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the pricing of an underwritten public offering of 4,489,796 million shares of common...

Feb 10, 2014, 16:13 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Proposed Public Offering of Common Stock

 PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has commenced an underwritten public offering of approximately $75 million of...

Jan 30, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

 PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz, Ph.D. has been...